Other

Institut Pasteur

Transgene S.a.

Transgene S.a., Institut Pasteur

Transgene S.a. and Institute Pasteur

Guy Rautmann

Luc Montagnier

Marie-Paule Kieny

Marc Girard

Jean-Pierre Lecocq

Simon Wain Hobson

Barbara Cordell

Ronald P Mischak

Jan Marian Scardina

Rebecca Pruss

John Huggins

The invention relates to the design, construction and use of eukaryotic cell lines useful in the identification of inhibitors of &bgr;-amyloid processing. More specifically, the invention relates to in vitro assays capable of identifying or quantifying a 4.2 kDa &bgr;-amyloid protein. The present invention also provides for DNA and protein molecules for the design, construction and use of eukaryotic cell lines useful in the identification of inhibitors of &bgr;-amyloid processing.

Assays for &bgr;-amyloid processing

This invention relates to an immunogenic composition comprising a viral vector. The genome of the viral vector comprises a functional origin of replication of a poxvirus, a DNA fragment encoding a non-cleavable gp160, a DNA fragment encoding a signal peptide, and a promoter for expressing DNA fragments in mammalian cells.

Viral vector coding for a glycoprotein of the virus responsible for

A viral vector comprising at least a portion of the genome of the HIV virus, a gene encoding gp160 glycoprotein of the envelope of the HIV virus, as well as the elements providing for the expression of the glycoprotein in cells, wherein the gp160 is expressed as a non-cleavable protein.

Non-cleavable GP160 glycoproteins of HIV

A viral vector comprising at least a portion of the genome of the HIV virus, a gene coding gp160 glycoprotein of the envelope of the HIV virus, as well as the elements providing for the expression of the glycoprotein in cells, wherein the gp160 is expressed as a non-cleavable protein.

Viral vector coding glycoprotein of HIV-1

Growing community of inventors

Strasbourg, France

Guy Rautmann